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ABSTRACT 
 
Alzheimer’s disease is a complex neurodegenerative disorder that affected 5.2 million people in 
America in 2014
[1]
. A large number of genome-wide association studies (GWAS) have been 
performed, which have been supplemented more recently by the first epigenome-wide association 
studies (EWAS), leading to the identification of a number of novel loci altered in disease. Twin studies 
have shown monozygotic twin discordance for Alzheimer’s disease[2], leading to the conclusion that a 
combination of genetic and epigenetic mechanisms are likely to be involved in disease etiology
[3]
. This 
review focuses on identifying overlapping pathways between published GWAS and EWAS studies, 
highlighting dysfunctional synaptic, lipid metabolism, plasma membrane/cytoskeleton, mitochondrial 
and immune cell activation pathways. Identifying common pathways altered in genetic and epigenetic 
studies will aid our understanding of disease mechanisms and identify potential novel targets for 
pharmacological intervention. 
 
 
 
 
KEYWORDS 
Alzheimer's disease; AD; DNA methylation; GWAS; EWAS; exome sequencing 
 
 
 
 
 
 
 
 
 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
INTRODUCTION 
 
Dementia encompasses a group of chronic neurodegenerative diseases that affected an estimated 
44.4 million people worldwide in 2013. Due to an increasingly aging population, it is predicted that this 
figure will rise to an estimated 75.6 million by 2030, and 135.5 million by 2050
[4]
. The worldwide cost 
of dementia in predicted to be in excess of $1,000 billion by 2030
[5]
. Alzheimer’s disease (AD) is the 
most common form of dementia accounting for ~60-80% cases worldwide
[6]
. AD is characterized by 
the accumulation of extracellular amyloid-β (Aβ) plaques, intracellular neurofibrillary tangles of 
hyperphosporylated tau, and widespread gliosis in the brain
[7]
. Despite the progress that has been 
made in understanding the cellular pathology of AD, available treatments only temporarily alleviate 
some symptoms and do not modify the underlying disease process. By the time an individual 
becomes symptomatic there is already considerable neuronal cell loss, plaque deposition and tangle 
burden within the brain, which can appear up to ten years before a clinical diagnosis is made
[8]
. 
Reflecting the growing public health and socioeconomic burden of AD there has been a year on year 
increase in the number of publications investigating the etiology of the disease (Figure 1) as 
researchers seek novel disease-modifying treatments. 
 
 
Although the neuropathology associated with AD has been well-described, little is known about the 
mechanisms underlying disease onset and progression. Quantitative genetic analyses demonstrated 
high heritability estimates (58%-79%) for AD
[9]
, and thus initial approaches to understanding etiology 
focused on uncovering a genetic contribution to disease susceptibility. In recent years, the recruitment 
of large cohorts and the relatively inexpensive cost of assessing genetic variation through genome-
wide association studies (GWAS) have allowed the identification of multiple variants associated with 
an elevated risk of developing AD. Many of these genes have also been robustly associated with AD 
via subsequent meta-analyses
[10-13]
 and, most recently, polygenic risk scores for AD have been 
developed
[14]
. Collectively, common SNPs are believed to only account for 33% of attributable risk
[15]
 
and the mechanism behind their action remains largely unknown. Exome-sequencing projects have 
also identified other variants e.g. TREM2
[16]
, which have a larger effect size, yet these are relatively 
rare. In recent years researchers have used epigenome-wide association studies (EWAS) to identify 
epigenetic changes in disease with the aim to elucidate additional mechanisms of pathology, which 
may provide a link to environmental factors.  
 
Epigenetic processes mediate the reversible regulation of gene expression, occurring independently 
of DNA sequence variation, acting principally through chemical modifications to DNA and 
nucleosomal histone proteins. Dynamic changes to the epigenome orchestrate a diverse range of 
important neurobiological and cognitive processes in the brain
[3]
. DNA methylation is the best 
characterized and most stable epigenetic modification which modulates the transcription of 
mammalian genomes. This is due to its ability to be interrogated using archived genomic DNA 
resources, which are the focus of most human epidemiological epigenetic research to date
[3]
. The 
methylation of a cytosine in a CpG dinucleotide by DNA methyltransferase (DNMT) enzymes, forms 5-
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methylcytosine (5-mC), which can disrupt the cell’s transcriptional machinery by blocking the binding 
of transcription factors and attracting methyl-binding proteins that initiate chromatin compaction and 
bring about gene silencing
[17]
. The predominant focus to date is methylation within CpG Islands (CGIs) 
located within the 5’ promoters of many constitutively expressed housekeeping control genes. 
However recent data suggests that the relationship between DNA methylation and transcription may 
be more complex, with gene body methylation and non-CpG methylation often being associated with 
active gene expression
[18-21]
 and alternative splicing
[22, 23]
. The mechanisms involved in cytosine 
demethylation have also been studied; its demethylation by Ten-eleven translocation (TET) enzymes 
leads to a stepwise change in the cytosine side chain state, from methylated cytosine to 
hydroxymethylated cytosine (5-hmC), to formyl cytosine (5-fC), to carboxyl cytosine (5-caC) and 
finally back to unmodified cytosine by a yet unclassified enzyme/mechanism
[24]
. Each of these 
intermediates may have their own effect on gene transcription, splicing and subsequent protein 
function, and recent studies have shown 5-hmC to be at high levels in the brain
[25, 26]
, with variation 
across different anatomical regions
[27]
. Recent advances in genomic technology have allowed the first 
genome-scale studies assessing methylomic variation (EWAS) in AD. These studies have identified 
AD-associated DNA methylomic variation at numerous loci in the cortex, with consistent findings 
across multiple independent study cohorts, in addition to brain-region specific changes and blood 
DNA methylation signatures
[28, 29]
. In addition, a recent paper by Yu et al. combined genetic and 
epigenetic findings by examining DNA methylation patterns across genes that have previously been 
nominated by GWAS, identifying several overlapping loci
[30]
.  
 
Although GWAS and EWAS analyses have identified multiple genes associated with AD, the extent to 
which common pathways are shared in the findings across studies has not yet been explored. This 
review aims to integrate the most robust findings from GWAS, exome sequencing studies and EWAS 
performed to date in AD to highlight common molecular pathways, which could ultimately aid in the 
identification of novel pharmacological targets for the disease.  
 
 
METHODS 
 
Using the publically available online search – GWAS catalogue 
https://www.ebi.ac.uk/gwas/search?query=Alzheimer%27s%20disease#association and a P value cut 
off of P< 5x10
-8
, we identified 45 unique GWAS in AD totalling 144 SNPs. We then removed studies 
based on poor sample size (<1000 total samples) as well as removing those studies that included 
samples that were non-European in origin. Following the study selection, SNPs in intronic regions 
were removed from the analysis. After filtering for associated disease outcome measures, including 
the terms: “Dementia and core Alzheimer’s disease neuropathological changes”, “Alzheimer’s disease 
late onset”, “Alzheimer’s disease”, “Psychosis and Alzheimer’s disease”, “Alzheimer’s disease age of 
onset”, “Alzheimer’s disease biomarkers” and “Neurofibrillary tangles” we were left with 29 studies 
with 49 SNPs in 32 unique genes (Table 1A)[10-13, 31-48]. Four genes were identified from exome 
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sequencing studies
[16, 49-51]
 by performing a literature search in PubMed using the phrases 
“Alzheimer’s disease” and “Exome sequencing” alone and in combination (Table 1B). Genes from 
EWAS were compiled from the 2014 publications by Lunnon et al. and De Jager et al. including 
probes with P<1x10
-7[28, 29]
. The 2012 publication by Bakulsk et al. was excluded from the analysis 
based on sample size
[52]
. Gene names were checked against quoted genomic location using the 
UCSC genome browser, only genes containing a probe of interest were included. The resulting gene 
list contained 48 unique genes that met the criteria for inclusion for our study (Table 2). Gene 
annotation for all genes of interest were taken from the Gene Ontology (GO) Consortium database, 
where available, and supplemented with information from the Entrez gene database. Two genes 
overlapped between GWAS and exome sequencing studies (TREM2, SORL1) and one gene 
overlapped between GWAS and EWAS (BIN1), bringing the total number of genes across all 
analyses to 81. 
 
PATHWAYS 
 
The 81 genes identified were compared in terms of their molecular/cellular function and grouped by 
pathways in which the identified genes operate. By taking significant loci across multiple study 
designs, we identified five common pathways altered at the genetic and/or epigenetic level in AD; 
plasma membrane and cytoskeletal processes, lipid homeostasis, synaptic signalling, immune cell 
processes and mitochondrial processes (Figure 2). The largest number of genes fell into the 
functional group plasma membrane and cytoskeletal processes (n=14), however this could be due to 
the fact that this is a proportionally larger pathway and is therefore more likely to contain an 
associated gene by chance. Of the pathways we have identified many of them have considerable 
overlap, for example lipid processes are intrinsically linked to the plasma membrane which is 
composed of phospholipids and a large percentage of cholesterol. To better understand the overlap 
between GWAS and EWAS nominated genes we looked at the cellular localization of genes from 
each type of study (Figure 3). The two largest localization groups (cellular membrane and nucleus) 
were consistent between methodologies. This would, to some degree, be expected as the majority of 
total proteins are involved in these locations and, in addition, current protein research has focused on 
these areas of the cell.  
  
To provide a more structured approach to pathway analysis, all 81 genes were entered into the 
PANTHER pathway analysis using the enrichment analysis from gene ontology consortium
[53]
. 
Fourteen biological process and four cellular component pathways were identified after passing 
Bonferroni correction. Most pathways reflected an interaction with Aβ or other AD pathology (Figure 
4). As the data for these genes was most likely collected from AD publications the resulting pathways 
are not unexpected, but are most likely to be limited.  
 
Plasma Membrane / Cytoskeleton 
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This is the pathway which contained the largest number of associated genes from our analysis 
(n=14). The plasma membrane insulates the intracellular components from the extracellular 
environment, as well as catalyzing the transport of specific compounds, including nutrients and ions. 
Phospholipids that make up the membrane provide suitable fluidity and permeability. Alterations in the 
receptor function, membrane integrity, and membrane-dependent processes seen in AD have been 
reviewed by A. Farooqui et al
[54]
. The cytoskeleton provides contractility and couples biochemical 
responses with mechanical stresses in cells. It is vital in the movement of cellular machinery around 
the cell and to the membrane, as well as orchestrating the procedures needed for cellular movement 
and re-shaping, a function specifically important to the microglial cells of the brain in the response to 
inflammation
[55]
. For an overview of cell mechanics and the cytoskeleton see the review by Fletcher 
and Mullins 2010
[56]
. The inability of neurons to regulate calcium homeostasis through cell surface ion 
channels is an aspect of AD pathogenesis that appears to be intimately involved in the dysfunction 
and death of neurons
[57]
. Familial AD mutations in APP and PSEN1 support a role for perturbed 
calcium regulation in AD
[57]
. In addition, all of the enzymatic machinery responsible for the generation 
of the pathogenic Aβ plaque formation are plasma membrane based
[58]
; suggesting that damage to 
the plasma membrane may be a key factor in the Aβ pathology typical of AD.   
 
BIN1 has been nominated by both GWAS and EWAS, and in addition to its role in synaptic signalling, 
it also has a role in plasma membrane/cytoskeletal processes as it acts as an amphiphysin, which are 
known to promote caspase-independent apoptosis as well as play an important role in neuronal 
membrane organization
[59]
. Major learning defects and seizures have been linked to decreased 
expression of amphiphysins in murine brain
[60]
. In addition, altered expression of BIN1 has been 
shown in aging mouse models of AD
[61]
, providing further evidence for its role in AD pathology. 
Despite having no previous link to AD, ANK1 is now the one of the strongest reported candidate 
genes in AD EWAS, with strong links to cell structure. ANK1 was found to be hypermethylated in AD 
brain in two separate studies, including one with two independent validation cohorts
[28, 29]
. The 
differentially methylated region (DMR) in this gene spans at least six CpG sites, and was significantly 
associated with neuropathology in cortical regions, but not cerebellum or pre-mortem blood
[28]
, 
indicating tissue-specificity of the DMR to regions of neuropathology. ANK1 is found in multiple 
different isoforms, with some transcript variants specific to the brain
[62]
, and some evidence for 
differential splicing in AD
[28]
. As with BIN1, one of the main functions of ANK1 is compartmentalization 
and maintenance of the plasma membrane, and it is possible that the altered expression of this gene 
could lead to neuronal membrane dysfunction in AD
[28]
.  
 
The PVRL2 gene identified by GWAS encodes a single-pass type I membrane glycoprotein, which is 
one of the plasma membrane components of adherens junctions. Cell to cell connections brought 
about by adherens junctions are vital for effective neuronal signalling
[63]
. Interestingly, Marambaud et 
al. using various immunological based methods to investigate the PSEN1/γ-secretase system, where 
mutations are associated with familial AD, and showed it disrupted adherens junctions in AD
[63]
. 
Expression of PVRL2 has been detected in many organs including the brain, and it was later 
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suggested it was associated with human longevity along with the AD GWAS nominated loci TOMM40 
and APOE
[64]. In addition, Elias-Sonnenschein et al., showed a significant correlation between the 
GWAS nominated locus MS4A4A and Aβ but not with tau pathology in AD
[65]
. Despite this, there is 
little-to-no research on the specific function of MS4A4A, although the gene product is associated with 
GO pathways that indicate it is an integral component of the plasma membrane. Two other genes 
within the MS4A gene cluster have also been nominated via GWAS; MS4A4E and MS4A6A
[11, 12]
. 
One recent study demonstrated that MS4A6A genotype and AD are associated with differential 
expression of isoform variants in blood and some brain regions
[66]
. 
 
 
Lipid Homeostasis   
Recent epidemiological, molecular and biochemical evidence has strengthened the hypothesis that 
cholesterol is a risk factor for AD, and although cholesterol homeostasis in the brain is largely 
unexplored, new findings strongly support the involvement of cholesterol in both the generation and 
deposition of Aβ
[67]
. Specifically, the quantity of cholesterol in the neuronal plasma membrane has 
been shown to make neurons more susceptible to the damage caused by Aβ in AD
[68]
. Other studies 
suggest that cholesterol acts directly on the amyloid cascade by promoting amyloidogenic processing 
of APP
[57]
. Interestingly, statins, which are a class of cholesterol-lowering drugs, decrease Aβ levels 
as well as plaque deposition in APP transgenic mouse models
[69]
. In addition high cholesterol levels 
and changes to cholesterol metabolism can increase the production of Aβ in cell culture and murine 
models
[67]
. Three of the most significant genes from AD GWAS are associated with lipid metabolism 
(APOE, APOC1, CLU). APOE was first identified as a risk factor for AD in 1993
[70]
, using immuno-
staining and genotyping analysis of 30 AD cases and 91 controls. Since 2006 and the wide 
application of GWAS to AD research
[71]
, the APOE polymorphism has been successfully replicated in 
several other studies
[31, 41, 72-75]
, making APOE the most robust gene linked to late-onset AD (LOAD) 
risk to date. The proportion of genetic variance for LOAD risk attributed to APOE genotype is 
estimated to be 10–20%
[76]
.
 
APOE is a 299 amino acid glycoprotein and the major protein component 
of very low-density lipoproteins (VLDL), the major apolipoprotein in the brain
[67]
, as well as having a 
functional role in cholesterol and triglyceride metabolism
[77]
. There are three APOE alleles that affect 
one’s risk of AD (2, 3 and 4), in addition to age of onset
[78]
. Of the three alleles; APOE 2 
demonstrates a protective effect, with an OR of 0.3 for possessing one 2 allele, whilst APOE 4 is 
associated with a higher LOAD risk, with an OR of 4.4 and 19.3 respectively for having one or two 
alleles
[79]
, as well as a younger median age of dementia onset
[79, 80]
. It has been suggested that the 
mutated APOE hinders clearance of soluble Aβ protein from the brain, leading to Aβ aggregation into 
fibrils. Furthermore, APOE has been shown to promote neurodegeneration by directing the toxic Aβ 
oligomers to synapses
[75]
. However, a recent PET study to measure Aβ in 602 individuals found that 
the ε4 allele is neither necessary, nor sufficient, for the development of AD pathology
[75]
.  
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Synaptic Signalling  
Synaptic dysfunction is possibly the best-established of all the proposed pathological mechanisms for 
AD to date as it shows clear progression throughout the entire disease, including pre-symptomatic 
changes
[83]
. Early stages of AD are characterized by a 25-35% decrease in numerical density of 
synapse per cortical region
[84]
. There has also been evidence that the loss of synapses correlates with 
the soluble pool of cortical Aβ
[85]
. Stereological and biochemical analyses have shown that the 
reduction in synaptic density within AD brain correlates with cognitive defects better than the 
traditional hallmarks of Aβ plaques and neurofibrillary tangles
[83]
.  
 
We have identified four genes from GWAS and EWAS analyses of AD that have been linked to 
synaptic function. Two of these, BIN1 and PICALM, have functions in vesicular trafficking. 
Specifically, studies have shown that the BIN1 gene has roles in a number of specific pathways, 
including clathrin-mediated endocytosis (CME) which is an essential step in the intracellular trafficking 
of proteins and lipids such as nutrients, growth factors and neurotransmitters in synapses
[86-88]
. 
Originally identified as a tumour suppressor
[89]
, the BIN1 gene product is expressed most abundantly 
in brain and muscle
[90]
, with several alternatively spliced brain specific isoforms. BIN1 is one of the few 
genes that has been reproducibly identified by GWAS that does not fall near or within the APOE 
locus, in addition it is the only gene in our analysis to be significantly associated with AD in both 
GWAS and EWAS.  
 
Like BIN1, PICALM is also involved in CME
[87]
. PICALM directs the trafficking of the VAMP2 protein. 
VAMP2 is a SNARE protein that plays a key role in the fusion of vesicles to the presynaptic 
membrane allowing neurotransmitter release into the synapse, a process essential to neuronal 
function
[91]
. PICALM has been robustly identified as a risk factor for AD via GWAS
[10, 37]
, however, AD 
linked SNPs identified in PICALM may still be affected by APOE genotype, due to the large amount of 
attenuation seen when adjusted for APOE status
[45]
. Jun et al. have also reported this interaction 
observing that genotypes of PICALM conferred risk predominantly in APOE ε4–positive participants, 
providing strong evidence for a synergistic effect
[92]
. PICALM is also thought to affect amyloid 
precursor protein (APP) processing via endocytic pathways
[10]
.  
 
As a previously known risk factor gene for AD
[12]
, PTK2B was shown via network analyses to be 
linked to RHBDF2, ANK1 and RPL13, which were recently nominated from EWAS and providing 
further evidence for a role in AD pathology
[29]
. PTK2B has a number of roles including the induction of 
long term potentiation (LTP) of nerve cells, a central process of memory formation; cell migration and 
synaptic function
[12]
. 
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Immune cell dysfunction (Astrocytes, Oligodendrocytes & Microglia) 
There is a widely accepted link between inflammation, the immune system and AD pathology
[93-97]
, 
more specifically the inflammation seen in AD has been proposed to exacerbate symptoms
[94]
. 
Microglia, which are the brain’s resident macrophages, have been shown to increase their viability by 
22.0~29.4% in response to fibular Aβ deposits of 0.2 to 5.0μM, which are commonly seen in AD. 
Oligomeric Aβ at a dose of 5.0μM results in cytotoxic microglia
[98]
 and ultimately leads to synaptic 
degeneration and neuronal death
[99]
. However, relatively few genes that have shown robust 
associations with AD have been directly linked with inflammation or immune functions. Most 
noteworthy a rare variant in TREM2, was recently recognised by a number of AD exome sequencing 
studies and GWAS
[16, 48, 100, 101]
. TREM2 encodes an innate immune system receptor on the surface of 
microglial cells within the brain. With the signalling counterpart DAP12 (also called TYROBP), TREM2 
forms a molecular complex that promotes phagocytosis of bacteria
[102]
. Work by Takahashi et al. has 
shown that TREM2 also has a role in the clearance of apoptotic neurones, due to its ability to 
increase migration and phagocytosis of microglia
[103]
. Recently one study demonstrated correlation in 
TREM2 and CD33 gene expression in AD
[104]
. As CD33 has also been nominated in various AD 
GWAS
[11, 13, 35]
 this provides further evidence for an overlap of AD gene pathways in disease. As 
described above, recent protein-protein interaction data also demonstrated that several EWAS 
nominated loci (ANK1, RHBDF2, PICLAM) have a functional link to PTK2B
[29]
. PTK2B is an AD risk 
factor gene that plays a key role in the signalling cascade involved in the modulation of microglial and 
infiltrating macrophage cell activation
[29]
.  
 
A further gene related to immune function is RHBDF2, identified by EWAS. Differentially methylated 
CpG sites close to the RHBDF2 gene were identified in two independent EWAS
[28, 29]
, with recent 
studies showing this increases RHBDF2 expression in AD brain
[29]
. RHBDF2 transports TNFα 
converting enzyme (TACE, also called ADAM17), which is necessary for the release of TNFα from the 
cell surface
[105]
. RHBDF2 absence in mice affects the release of TNFα from the cell surface
[106]
 and 
therefore impairs systemic immune responses to pathogens
[107]
, although the brain phenotype has yet 
to be researched.  
 
Mitochondrial Processes  
Mitochondrial dysfunction is one of the most prominent characteristics of AD, in both the brain and the 
periphery
[108-110]
, with TOMM40, one of the most robust genes identified from GWAS, associated with 
mitochondrial function. This gene is located approximately 2kb downstream from APOE and due to 
the locality of these two genes there is strong linkage disequilibrium (LD) for TOMM40 with the APOE 
locus
[111]
, hence many studies have failed to find an association of TOMM40 in AD after adjusting for 
APOE genotype[75, 112, 113]. However, one study reports TOMM40 as a possible risk factor of AD 
independent of APOE
[114]
. Specifically this study found a poly-T track mutation in TOMM40 that acts 
independently of APOE genotype, which has also seen been reported in another independent 
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study
[115]
. In addition to increasing risk of developing AD, TOMM40 has also been linked to an earlier 
age of onset for the disease
[116]
. Other studies also suggest that TOMM40 provides an additional risk 
for AD, in addition to APOE
[117, 118]
. However, until the extent of the LD between TOMM40 and APOE 
is fully characterized, it will be difficult to pinpoint the exact effect the TOMM40 mutation has on LOAD 
pathogenesis.   
 
CLU has various nuclear and mitochondrial isoforms and is thought to regulate the rate of cell 
proliferation. CLU has been consistently replicated across many GWAS and holds a strong 
association with AD
[10, 36, 92, 112]
. The nuclear isoforms result in the promotion of apoptosis, whereas 
mitochondrial isoforms of CLU suppress BAX-dependent release of cytochrome c into the cytoplasm 
and inhibit apoptosis
[119]
. As an increased level of apoptosis in the brain is seen in AD, it could 
suggest a role of CLU mutations in pathogenesis
[120]
. SPG7 was identified by EWAS and encodes a 
mitochondrial metalloprotease protein. Mitochondrial proteases degrade misfolded and non-
assembled polypeptides. They also regulate the activity of specific substrates by mediating essential 
processing steps. These proteases have been hypothesized to play a role in neurodegenerative 
diseases by affecting neuronal maintenance and axonal function
[121]
. 
 
DISCUSSION 
 
The use of GWAS to identify common disease variants in AD has been at the forefront of research to 
understanding disease etiology for 10 years. More recently, the falling cost of exome and whole 
genome sequencing has identified rarer variants with a larger effect size. However, only three EWAS 
have been reported in AD to date
[28, 29, 52]
, which have solely focussed on DNA methylation,
 
although 
further studies are highly anticipated. Of all the genes identified from GWAS and EWAS in AD, only 
one locus was found to be overlapping between these two methodologies (BIN1).  
 
As with any pathway identification analysis there are caveats to our method. Some pathways are 
significantly larger than others containing more genes, therefore using this method we are more likely 
to find associated genes in these pathways over others.  Secondly, cellular pathways that contain a 
gene which is either genetically or epigenetically altered may still be able to function normally, as 
similar proteins could “step-in” to fulfil the lost functionality. Thirdly, in our analysis we did not filter our 
results based on loss of function SNPs or reduced expression, therefore despite the alterations in AD 
the genes we have identified may well have no change in their functionality. Fourthly, AD is 
characterised by neuronal cell loss and gliosis, and thus the findings from EWAS may simply 
represent an alteration in cellular abundance and although EWAS studies can apply cell specific 
corrections to methylation data
[122]
, this was not included in our analysis. The ability to look at single 
cell epigenetic profiles in disease would allow researchers to conclusively quantify changes that occur 
at both cellular and disease state levels, however single cell isolation in post mortem tissue, via laser 
capture microdissection (LCM) or florescent-assisted cell sorting (FACS), currently represents a 
considerable challenge to the field. Finally, epigenetic research in AD is still in its early stages with 
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only two EWAS included in our analysis, this coupled with the fact that current methylation data is the 
sum of two different cytosine modifications (5-mC and 5-hmC) means we may have an 
underrepresentation of significant EWAS genes in AD. A further caveat of epigenetic studies 
compared to genetic studies is that causality is more difficult to establish and thus further studies 
examining the functional role of nominated EWAS loci are warranted. 
 
 
 
CONCLUSION 
 
Looking at the most-significant genetic and epigenetic findings in AD to date we have identified 
several pathways that require further exploration and could ultimately aid in our understanding of AD 
etiology. Well characterized clinical cohorts will also allow the identification of further rare variants of 
AD, whilst advances in methodologies are also allowing the identification of other epigenetic marks, 
such as histone modifications and other DNA modifications at single nucleotide resolution
[3, 123]
. A 
number of recent studies have demonstrated altered global levels of 5-hmC in AD brain
[124, 125]
, 
however studies to investigate loci-specific 5-hmC changes in AD are yet to be published. There is 
also the potential for further disease mechanisms to be identified from current studies as research 
moves to integrate GWAS and EWAS data in the same datasets to identify cis methylation 
quantitative trait loci (mQTLs). Ultimately integrating genomic and epigenomic data with other “omic” 
modalities will allow the identification of novel dysfunctional pathways in disease
[3]
.   
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Table 1A: Genes nominated from GWAS studies. Shown are the genes identified from GWAS studies 
and their respective SNPs, associated P-value, GO annotation, chromosome and genomic position 
and the relevant study. SNPs of P<5x10-8  were only included. 
Gene SNPs 
Identifi
ed 
P-
valu
e 
GO annotation Chromo
some 
Positio
n 
Title of 
Paper 
First 
Author  
and Year 
Refere
nce 
ABCA7 rs3764
650 
5.00
E-
17 
GO:0005215 
transporter 
activity 
GO:0005524 
ATP binding  
GO:0005548 
phospholipid 
transporter 
activity  
GO:0016887 
contributes_to 
ATPase activity 
19 104652
1 
Common 
variants at 
ABCA7, 
MS4A6A/M
S4A4E, 
EPHA1, 
CD33 and 
CD2AP are 
associated 
with 
Alzheimer's 
disease. 
Holling
worth, 
2011 
[11] 
 rs4147
929 
1.00
E-
15 
 19 106344
4 
Meta-
analysis of 
74,046 
individuals 
identifies 11 
new 
susceptibility 
loci for 
Alzheimer's 
disease. 
Lambert, 
2013a 
 
[12] 
 
APOE, 
APOC1,TO
MM40 
rs4420
638 
1.00
E-
39 
APOE 
GO:0001540 
beta-amyloid 
binding IDA 
11305869 
GO:0005319 
lipid transporter 
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Table 1B: Genes nominated from exome sequencing studies. Shown are the genes identified from 
exome sequencing  studies and their respective SNPs, GO annotation, chromosome and genomic 
position and the relevant study. 
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Title of Paper First 
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Table 2: Genes nominated from EWAS studies. Shown are the genes identified from EWAS studies 
and their respective probes, associated P-value, GO annotation, chromosome and genomic position 
and the relevant study. Probes of P<1x10-7  were only included. 
Gene Probes 
Identified 
P-
value 
Functional 
summary, GO 
annotation 
Chromoso
me 
Position Title of 
Paper 
First 
Autho
r and 
Year 
Referen
ce 
ABR cg250184
58 
1.89
E-10 
GO:0005089 
Rho guanyl-
nucleotide 
exchange factor 
activity  
GO:0005096 
GTPase activator 
activity 
17 980014 Methylo
mic 
profiling 
implicate
s cortical 
deregulati
on of 
ANK1 in 
Alzheime
r's disease 
Lunno
n, 
2014 
[28] 
ALDH16
A1 
cg206184
48 
1.16
E-08 
GO:0004029 
aldehyde 
dehydrogenase 
(NAD) activity 
19 4996232
4 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
ANK1 cg050669
59 
7.13
E-14 
GO:0005198 
structural 
molecule activity  
GO:0005200 
structural 
constituent of 
cytoskeleton  
GO:0005515 
protein binding                                                           
 GO:0008093 
cytoskeletal 
adaptor activity  
GO:0019899 
enzyme binding  
GO:0030507 
spectrin binding 
GO:0051117 
ATPase binding 
8 4151930
8 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
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  1.24
E-09 
 8 4151930
8 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29 
 cg118231
78 
7.83
E-14 
 8 4151939
9 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
  3.42
E-11 
 8 4151939
9 
Methylo
mic 
profiling 
implicate
s cortical 
deregulati
on of 
ANK1 in 
Alzheime
r's disease 
Lunno
n, 
2014 
[28] 
 cg161405
58 
1.85
E-08 
 8 4151403
9 
Methylo
mic 
profiling 
implicate
s cortical 
deregulati
on of 
ANK1 in 
Alzheime
r's disease 
Lunno
n, 
2014 
[28] 
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ASGR2 cg186595
86 
1.06
E-09 
GO:0004873 
asialoglycoprotei
n receptor 
activity  
GO:0005515 
protein binding  
GO:0030246 
carbohydrate 
binding 
17 7017474 Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
ATG16L
2 
cg218062
42 
3.71
E-10 
Regulation of 
autophagy 
11 7253289
1 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
BCAR3 cg023421
48 
1.60
E-08 
GO:0005085 
guanyl-
nucleotide 
exchange factor 
activity  
GO:0005515 
protein binding 
1 9414522
3 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
BIN1 cg228832
90 
3.73
E-08 
GO:0005515 
protein binding  
GO:0032403 
protein complex 
binding 
GO:0042802 
identical protein 
binding  
2 1278006
46 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
De 
Jager, 
2014 
[29] 
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GO:0046982 
protein 
heterodimerizatio
n activity 
GO:0048156 tau 
protein binding 
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
CDA cg264075
44 
2.10
E-10 
GO:0001882 
nucleoside 
binding  
GO:0004126 
cytidine 
deaminase 
activity  
GO:0005515 
protein binding  
GO:0008270 
zinc ion binding 
1 2094535
5 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
CDH23, 
C10orf54 
cg239684
56 
1.09
E-08 
GO:0005509 
calcium ion 
binding 
GO:0005515 
protein binding 
10 7352163
1 
Methylo
mic 
profiling 
implicate
s cortical 
deregulati
on of 
ANK1 in 
Alzheime
r's disease 
Lunno
n, 
2014 
[28] 
  3.97
E-10 
 10 7352163
1 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
CXXC5 cg073545
06 
9.26
E-08 
GO:0004871 
signal transducer 
activity  
GO:0005515 
protein binding  
GO:0008134 
5 1390481
48 
Methylo
mic 
profiling 
implicate
s cortical 
deregulati
Lunno
n, 
2014 
[28] 
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transcription 
factor binding 
GO:0008270 
zinc ion binding 
on of 
ANK1 in 
Alzheime
r's disease 
FOXK1 cg071805
38 
4.95
E-08 
GO:0000977 
RNA polymerase 
II regulatory 
region sequence-
specific DNA 
binding 
GO:0000981 
sequence-specific 
DNA binding 
RNA polymerase 
II transcription 
factor activity 
GO:0005515 
protein binding 
7 4786899 Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
 cg255941
00 
2.54
E-11 
 7 4786943 Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
GMDS cg077148
12 
3.81
E-08 
GO:0005515 
protein binding  
GO:0008446 
GDP-mannose 
4,6-dehydratase 
activity  
GO:0070401 
NADP+ binding 
6 1635611 Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
GUCY2D cg041571
61 
7.80
E-08 
GO:0004383 
guanylate cyclase 
activity  
GO:0004672 
17 7906847 Alzheime
r's 
disease: 
early 
De 
Jager, 
2014 
[29] 
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protein kinase 
activity  
GO:0004872 
receptor activity 
GO:0005524 
ATP binding 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
HMHA1 cg023085
60 
3.06
E-08 
GO:0005096 
GTPase activator 
activity  
GO:0005515 
protein binding  
GO:0046872 
metal ion binding 
19 1071176 Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
ITM2C cg183467
07 
3.30
E-08 
GO:0001540 
beta-amyloid 
binding 
GO:0005515 
protein binding 
GO:0005524 
ATP binding 
2 2317322
49 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
ITPRIPL
2 
cg167332
98 
5.24
E-08 
membrane-
associated 
protein, 
intracellular 
calcium 
signalling 
16 1912713
2 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
De 
Jager, 
2014 
[29] 
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and other 
loci 
KCNN4 cg229047
11 
1.08
E-08 
GO:0005515 
protein binding                                                                                      
GO:0005516 
calmodulin 
binding  
GO:0015269 
calcium-activated 
potassium 
channel activity 
GO:0016286 
NOT small 
conductance 
calcium-activated 
potassium 
channel activity 
19 4427862
8
Alzheime
r's
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager,
2014 
[29] 
KDM2B cg117249
84 
4.76
E-09 
GO:0003677 
DNA binding  
GO:0005515 
protein binding  
GO:0008270 
zinc ion binding  
GO:0019843 
rRNA binding  
GO:0032452 
histone 
demethylase 
activity 
12 1218908
64 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
LNX1 cg121145
84 
5.81
E-13 
GO:0004842 
ubiquitin-protein 
transferase 
activity 
GO:0005515 
protein binding  
GO:0008270 
zinc ion binding  
GO:0016874 
ligase activity 
GO:0030165 
PDZ domain 
binding 
4 5451874
4 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
LYVE1 cg183438
62 
4.96
E-08 
GO:0004872 
receptor activity 
GO:0004888 
transmembrane 
signaling 
11 1059000
3 
Alzheime
r's 
disease: 
early 
alteration
De 
Jager, 
2014 
[29] 
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receptor activity  
GO:0005515 
protein binding  
GO:0005540 
hyaluronic acid 
binding 
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
MAFB cg135794
86 
3.25
E-08 
GO:0003700 
sequence-specific 
DNA binding 
transcription 
factor activity 
GO:0005515 
protein binding 
GO:0008134 
transcription 
factor binding 
GO:0043565 
sequence-specific 
DNA binding 
20 3931409
1 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
MCF2L cg078831
24 
6.31
E-12 
GO:0005089 
Rho guanyl-
nucleotide 
exchange factor 
activity 
GO:0005545 1-
phosphatidylinos
itol binding 
13 1136340
42 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
 cg094480
88 
6.43
E-10 
 13 1136356
90 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
De 
Jager, 
2014 
[29] 
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loci 
MYO10 cg067426
28 
1.58
E-10 
GO:0005515 
protein binding  
GO:0005516 
calmodulin 
binding  
GO:0005524 
ATP binding  
GO:0005547 
phosphatidylinos
itol-3,4,5-
trisphosphate 
binding 
5 1688642
4 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
MYO1C cg054176
07 
2.25
E-08 
GO:0003774 
motor activity  
GO:0003779 
actin binding  
GO:0005102 
receptor binding 
GO:0005515 
protein binding  
GO:0005516 
calmodulin 
binding 
17 1373605 Methylo
mic 
profiling 
implicate
s cortical 
deregulati
on of 
ANK1 in 
Alzheime
r's disease 
Lunno
n, 
2014 
[28] 
  2.52
E-08 
 17 1373605 Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
PASK cg254882
84 
3.50
E-08 
GO:0004674 
protein 
serine/threonine 
kinase activity 
GO:0004871 
signal transducer 
activity 
2 2420481
27 
Methylo
mic 
profiling 
implicate
s cortical 
deregulati
on of 
Lunno
n, 
2014 
[28] 
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GO:0005515 
protein binding 
ANK1 in 
Alzheime
r's disease 
PCNT cg006212
89 
6.48
E-08 
GO:0005515 
protein binding  
GO:0005516 
calmodulin 
binding 
21 4785591
6 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
 cg041476
21 
1.39
E-08 
 21 4785602
0 
Methylo
mic 
profiling 
implicate
s cortical 
deregulati
on of 
ANK1 in 
Alzheime
r's disease 
Lunno
n, 
2014 
[28] 
 cg234495
41 
9.39
E-08 
 21 4785589
3 
Methylo
mic 
profiling 
implicate
s cortical 
deregulati
on of 
ANK1 in 
Alzheime
r's disease 
Lunno
n, 
2014 
[28] 
PLAT cg176932
22 
2.14
E-08 
GO:0004252 
serine-type 
endopeptidase 
activity 
GO:0005515 
protein binding 
8 4203347
2 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
De 
Jager, 
2014 
[29] 
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and other 
loci 
PLXNC1 cg128773
35 
2.36
E-11 
GO:0004872 
receptor activity 
GO:0005102 
receptor binding 
GO:0005515 
protein binding 
12 9453931
9 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
PODXL cg087371
89 
3.37
E-08 
GO:0005515 
protein binding 
7 1312234
17 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
 cg191408
34 
1.22
E-09 
 7 1312176
68 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
PSMA1 cg274437
79 
1.18
E-08 
GO:0003723 
RNA binding  
GO:0004298 
threonine-type 
11 1466479
3 
Alzheime
r's 
disease: 
early 
De 
Jager, 
2014 
[29] 
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ED
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endopeptidase 
activity 
GO:0005515 
protein binding 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
PSTPIP1 cg116524
96 
2.57
E-09 
GO:0003779 
actin binding 
GO:0005515 
protein binding 
GO:0019903 
protein 
phosphatase 
binding 
15 7732452
6 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
RBM33 cg136399
01 
1.54
E-13 
GO:0000166 
nucleotide 
binding 
GO:0044822 
poly(A) RNA 
binding 
7 1555565
90 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
 cg144309
43 
2.71
E-10 
 7 1555566
52 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
De 
Jager, 
2014 
[29] 
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and other 
loci 
RHBDF2 cg058103
63 
9.42
E-10 
GO:0004252 
serine-type 
endopeptidase 
activity 
GO:0019838 
growth factor 
binding 
17 7447527
0 
Methylo
mic 
profiling 
implicate
s cortical 
deregulati
on of 
ANK1 in 
Alzheime
r's disease 
Lunno
n, 
2014 
[28] 
  3.68
E-10 
 17 7447527
0 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
 cg121638
00 
2.66
E-08 
 17 7447535
5 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
 cg130768
43 
3.81
E-08 
 17 7447529
4 
Methylo
mic 
profiling 
implicate
s cortical 
deregulati
on of 
ANK1 in 
Lunno
n, 
2014 
[28] 
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ED
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Alzheime
r's disease 
  1.68
E-09 
 17 7447529
4 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
SH3PXD
2A 
cg190072
69 
2.96
E-09 
GO:0005515 
protein binding 
GO:0035091 
phosphatidylinos
itol binding 
10 1054205
01 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
SIX3 cg223857
02 
4.47
E-10 
GO:0000980 
RNA polymerase 
II distal enhancer 
sequence-specific 
DNA binding 
GO:0001205 
RNA polymerase 
II distal enhancer 
sequence-specific 
DNA binding 
transcription 
factor activity 
involved in 
positive 
regulation of 
transcription 
GO:0001222 
transcription 
2 4517588
1 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
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corepressor 
binding  
GO:0003700 
sequence-specific 
DNA binding 
transcription 
factor activity 
SLC15A4 cg066536
32 
9.77
E-08 
GO:0005290 L-
histidine 
transmembrane 
transporter 
activity 
GO:0015293 
symporter 
activity 
12 1292814
44 
Methylo
mic 
profiling 
implicate
s cortical 
deregulati
on of 
ANK1 in 
Alzheime
r's disease 
Lunno
n K 
[28] 
SLC16A3 cg070126
87 
6.19
E-09 
GO:0005515 
protein binding  
GO:0008028 
monocarboxylic 
acid 
transmembrane 
transporter 
activity 
GO:0015129 
lactate 
transmembrane 
transporter 
activity  
GO:0015293 
symporter 
activity  
GO:0015355 
secondary active 
monocarboxylate 
transmembrane 
transporter 
activity 
17 8019518
0 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
SPG7 cg031695
57 
7.95
E-09 
GO:0004222 
metalloendopepti
dase activity  
GO:0005515 
protein binding 
GO:0005524 
ATP binding  
GO:0008233 
peptidase activity  
GO:0008270 
zinc ion binding 
16 8959895
0 
Methylo
mic 
profiling 
implicate
s cortical 
deregulati
on of 
ANK1 in 
Alzheime
r's disease 
Lunno
n K 
[28] 
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  3.99
E-10 
 16 8959895
0 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
STK32C cg259177
32 
9.98
E-08 
GO:0004672 
protein kinase 
activity  
GO:0004674 
protein 
serine/threonine 
kinase activity  
GO:0004713 
protein tyrosine 
kinase activity 
null  
GO:0005524 
ATP binding 
GO:0016772 
transferase 
activity, 
transferring 
phosphorus-
containing 
groups 
10 1340383
95 
Alzheime
r's 
disease: 
early 
alteration
s in brain 
DNA 
methylati
on at 
ANK1, 
BIN1, 
RHBDF2 
and other 
loci 
De 
Jager, 
2014 
[29] 
TFAP2E cg174744
22 
1.56
E-08 
GO:0000977 
RNA polymerase 
II regulatory 
region sequence-
specific DNA 
binding  
GO:0000981 
sequence-specific 
DNA binding 
RNA polymerase 
II transcription 
factor activity  
GO:0042803 
protein 
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